ASCO 2017: Atezolizumab Plus Bevacizumab in Metastatic Renal Cell Carcinoma
The combination of the programmed cell death protein 1 (PD-L1) inhibitor atezolizumab and the monoclonal antibody bevacizumab may prove to be an effective first-line therapy for patients with metastatic renal cell carcinoma, according to the results of the phase II IMmotion150 trial. Michael B. Atkins, MD, of Georgetown-Lombardi Comprehensive Cancer Center in Washington, DC, presented the outcomes data from this clinical trial at the recent 2017 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 4505). The combination therapy may offer some benefit in the second-line setting as well for some patients with advanced disease.
In this multicenter, randomized study, 305 patients were assigned to the following treatment groups: arm 1: atezolizumab plus bevacizumab (101); arm 2: atezolizumab alone (103); or arm 3: sunitinib (101). More than half of these patients (164) had PD-L1–positive disease.
Nearly half of patients (48%) in the combination therapy arm responded to treatment, compared with 28% of those who received atezolizumab alone and 27% of patients who received sunitinib alone. The median progression-free survival also favored the combination therapy over the monotherapy arms (11.7 vs 6.1 months with atezolizumab alone and 8.4 months with sunitinib alone). For those who had PD-L1–positive disease in the combination therapy arm, the median progression-free survival was 14.7 months.
The investigators are studying atezolizumab plus bevacizumab further in this patient population, comparing this combination with sunitinib in the ongoing phase III IMmotion151 trial.